Impact Partnership Wealth LLC Makes New $551,000 Investment in Merck & Co., Inc. $MRK

Impact Partnership Wealth LLC bought a new stake in shares of Merck & Co., Inc. (NYSE:MRK) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 4,578 shares of the company’s stock, valued at approximately $551,000.

Several other hedge funds also recently modified their holdings of the business. Kingdom Financial Group LLC. acquired a new position in Merck & Co., Inc. in the fourth quarter valued at approximately $25,000. Prosperity Bancshares Inc acquired a new stake in Merck & Co., Inc. during the 4th quarter worth $26,000. Abound Financial LLC acquired a new stake in Merck & Co., Inc. during the 4th quarter worth $26,000. IFC & Insurance Marketing Inc. bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $31,000. Finally, High Note Wealth LLC lifted its stake in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the period. Institutional investors own 76.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MRK. Wells Fargo & Company reduced their price target on Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating on the stock in a research report on Friday, May 1st. UBS Group increased their target price on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. Weiss Ratings lowered Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Saturday, June 6th. Finally, Scotiabank upped their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research note on Tuesday. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $131.83.

Merck & Co., Inc. Price Performance

MRK opened at $125.30 on Thursday. The stock has a market cap of $309.46 billion, a P/E ratio of 35.29, a P/E/G ratio of 2.62 and a beta of 0.19. Merck & Co., Inc. has a 12 month low of $76.66 and a 12 month high of $130.29. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The company has a fifty day simple moving average of $116.71 and a 200 day simple moving average of $115.06.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. During the same period in the previous year, the company posted $2.22 earnings per share. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts expect that Merck & Co., Inc. will post 5.19 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Investors of record on Monday, June 15th will be paid a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Bank of America raised its price target on Merck to $141 from $130 and reiterated a buy rating, citing improved upside potential. Bank of America raises Merck price target
• Positive Sentiment: Scotiabank lifted its price target to $155 from $136 and maintained an outperform rating, signaling stronger confidence in Merck’s valuation and earnings outlook. Scotiabank raises Merck price target
• Positive Sentiment: Erste Group slightly increased its FY2027 EPS estimate for Merck, reflecting modestly improved long-term earnings expectations. Erste Group EPS estimate update
• Positive Sentiment: Merck announced it will hold its second-quarter 2026 sales and earnings conference call on Aug. 4, keeping investors focused on upcoming results and guidance. Merck earnings conference call announcement
• Neutral Sentiment: Merck also hit a new 52-week high following the analyst upgrade, but the stock has since pulled back after its six-day advance, suggesting some profit-taking. Merck sets new 52-week high on analyst upgrade
• Negative Sentiment: U.S. lawmakers launched a national security probe into Merck’s clinical trial activities in China, raising concerns about data protection, oversight, and exposure to politically sensitive trial sites. Merck faces U.S. security probe over China clinical trials
• Negative Sentiment: Broader healthcare weakness also weighed on sentiment, with the sector lower late Tuesday afternoon. Healthcare stocks softer late afternoon

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.